These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 28921646)
1. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved? McKee AE; Markon AO; Chan-Tack KM; Lurie P J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646 [TBL] [Abstract][Full Text] [Related]
2. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. Puthumana J; Miller JE; Kim J; Ross JS JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072 [TBL] [Abstract][Full Text] [Related]
3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
4. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation? Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691 [TBL] [Abstract][Full Text] [Related]
5. Expanded access to investigational drugs for treatment use. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173 [TBL] [Abstract][Full Text] [Related]
6. Practical, legal, and ethical issues in expanded access to investigational drugs. Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952 [No Abstract] [Full Text] [Related]
7. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Speers MA Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253 [TBL] [Abstract][Full Text] [Related]
8. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill. Ochs A Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540 [No Abstract] [Full Text] [Related]
9. Impact of Expanded Access on FDA Regulatory Action and Product Labeling. Jarow JP; Moscicki R Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277 [TBL] [Abstract][Full Text] [Related]
10. Comparing patient access to pharmaceuticals in the UK and US. Cohen J; Cairns C; Paquette C; Faden L Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032 [TBL] [Abstract][Full Text] [Related]
11. Individual patient treatment use of unapproved drugs: a new option for the seriously ill. Simon LS; Green A J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195 [TBL] [Abstract][Full Text] [Related]
12. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients. Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080 [TBL] [Abstract][Full Text] [Related]
13. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns. Goldman SA Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417 [TBL] [Abstract][Full Text] [Related]
14. Charging for investigational drugs under an investigational new drug application. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172 [TBL] [Abstract][Full Text] [Related]
15. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. Finkelstein PE AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587 [No Abstract] [Full Text] [Related]
16. The terminally ill, access to investigational drugs, and FDA rules. Blake V Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785 [No Abstract] [Full Text] [Related]
17. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912 [TBL] [Abstract][Full Text] [Related]
18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
19. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period. Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324 [TBL] [Abstract][Full Text] [Related]
20. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation. Kwok M; Foster T; Steinberg M Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]